Robert Azelby

Mr. Robert W.
Azelby is a Chairman at Tango Therapeutics, Inc., an Independent Director at Cardinal Health, Inc. and an Independent Non-Executive Director at ADC Therapeutics SA. He is on the Board of Directors at Cardinal Health, Inc., Autolus Therapeutics Plc and ADC Therapeutics SA. Mr. Azelby was previously employed as an Independent Director by Terns Pharmaceuticals, Inc., a Chief Executive Officer by Masimo Corp., an Independent Director by Chinook Therapeutics, Inc., a President, Chief Executive Officer & Director by Eliem Therapeutics, Inc., an Independent Director by Clovis Oncology, Inc., a President, Chief Executive Officer & Director by Alder Biopharmaceuticals, Inc., a Chief Commercial Officer & Executive VP by Juno Therapeutics, Inc., a Vice President & General Manager-Oncology by Amgen, Inc., and a VP-Commercial Effectiveness Unit & General Manager by Amgen Europe BV.
He also served on the board at Immunomedics, Inc., CASCADIAN THERAPEUTICS INC and Alliance for Regenerative Medicine.
He received his undergraduate degree from the University of Virginia and an MBA from Harvard Business School.